Exposed to neutron flow, the phosphorus implanted TiNi alloy gets radioactive. This radioactive material is used in vascular stent for prevention and cure of restenosis. Phosphorus implantation is carried out in a plasma immerged ion implantation system, and the dose of phosphorus implantation is in the range of 2-10 x 10(17) cm-2. After ion implantation, the alloy is exposed to the slow neutron flow in a nuclear reactor, the dose of the slow neutron is 1.39-5.88 x 10(19) n/cm2. The radioactivity of the TiNi alloy was measured by liquid scintillation spectrometry and radio-chromic-film dosimetry. The result shows that whether the phosphorus is implanted or not, the TiNi alloy comes to be radioactive after exposure to neutron flow. Just after neutron irradiation, the radiation dose of phosphorus implanted TiNi alloy is about one hundred times higher than that of un-phosphorus implanted TiNi alloy. The radiation difference between phosphorus and un-phosphorus implanted alloy decreases as time elapses. Within three months after neutron irradiation, the average half-decay period of phosphorus implanted TiNi alloy is about 62 days. The radiation ray penetration of phosphorus implanted TiNi alloy is deeper than that of pure 32P; this is of benefit to making radiation uniformity between stent struts and reducing radiation grads beyond the edge of stent.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Application Progress of Nonthermal Plasma Technology in the Modification of Bone Implant Materials.
ACS Biomater Sci Eng
October 2024
School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, Anhui 230026, China.
With the accelerating trend of global aging, bone damage caused by orthopedic diseases, such as osteoporosis and fractures, has become a shared international event. Traffic accidents, high-altitude falls, and other incidents are increasing daily, and the demand for bone implant treatment is also growing. Although extensive research has been conducted in the past decade to develop medical implants for bone regeneration and healing of body tissues, due to their low biocompatibility, weak bone integration ability, and high postoperative infection rates, pure titanium alloys, such as Ti-6A1-4V and Ti-6A1-7Nb, although widely used in clinical practice, have poor induction of phosphate deposition and wear resistance, and Ti-Zr alloy exhibits a lack of mechanical stability and processing complexity.
View Article and Find Full Text PDFPreparation and characterization of polydopamine and -butyl methacrylate copolymer coatings on titanium-nickel alloy stents.
RSC Adv
May 2024
School of Materials Science and Engineering, East China University of Science and Technology Shanghai 200237 China
Cardiovascular diseases pose a significant global health threat, and stents play a crucial role in managing these diseases. However, challenges exist with respect to the poor adhesion of stent coatings. Cardiac stents are often composed of titanium-nickel (TiNi) alloys as the metallic component and poly(-butyl methacrylate) (PBMA) as the coating.
View Article and Find Full Text PDFCombined Porous-Monolithic TiNi Materials Surface-Modified with Electron Beam for New-Generation Rib Endoprostheses.
J Funct Biomater
May 2023
Laboratory of Medical Materials Science, Tomsk State University, 634050 Tomsk, Russia.
TiNi alloys are very widely used materials in implant fabrication. When applied in rib replacement, they are required to be manufactured as combined porous-monolithic structures, ideally with a thin, porous part well-adhered to its monolithic substrate. Additionally, good biocompatibility, high corrosion resistance and mechanical durability are also highly demanded.
View Article and Find Full Text PDFFrom the phenotype to precision medicine: an update on the cardiomyopathies diagnostic workflow.
J Cardiovasc Med (Hagerstown)
May 2023
Dipartimento Cardiotoracico, Ospedale Santa Maria della Misericordia, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), Udine, Italy.
Cardiomyopathies are disease of the cardiac muscle largely due to genetic alterations of proteins with 'structural' or 'functional' roles within the cardiomyocyte, going from the regulation of contraction-relaxation, metabolic and energetic processes to ionic fluxes. Modifications occurring to these proteins are responsible, in the vast majority of cases, for the phenotypic manifestations of the disease, including hypertrophic, dilated, arrhythmogenic and restrictive cardiomyopathies. Secondary nonhereditary causes to be excluded include infections, toxicity from drugs or alcohol or medications, hormonal imbalance and so on.
View Article and Find Full Text PDFOld and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy.
Eur Heart J Suppl
April 2023
Department of Clinical and Molecular Medicine, Sapienza University, Rome.
Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium that is relatively common in the general population, with an autosomal dominant inheritance as a genetic basis. Clinical and natural history pathways can be very different among patients with HCM. Treatment strategies have made very important advances in the last two decades, especially reducing cases of sudden death through effective risk stratification and the use of implantable defibrillators.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!